Improving outcomes in patients undergoing percutaneous coronary intervention: Role of prasugrel

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 475-481

  Motovska, Zuzana ^a   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Dual oral antiplatelet therapy; Oral thienopyridine; P2Y12 receptors; Prasugrel

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; THIOLACTONE; TICAGRELOR; TICLOPIDINE; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ATHEROSCLEROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; HEART INFARCTION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIA; LOADING DRUG DOSE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; STENT THROMBOSIS; STROKE; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; INSTRUMENTATION; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STENTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 67449097605     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s3969     Document Type: Review

References (58)

1. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996;27:15-21.
2. Makkar RR, Eigler S, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J. 1998;19:1538-1546.
3. Lenzen MJ, Boersma E, Bertrand ME, et al; European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J. 2005;26(12):1169-1179.
4. Thom T, Haase N, Rosamond W, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-e101.
5. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
6. Ibanez B, Vilahur G, Badimon JJ, Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl. 2006;8:G3-G9.
7. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624-629.
8. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine and clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9-14.
9. Silber S, Albertsson P, Aviles FF, et al; for Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26(8):804-847.
10. Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med. 2007;146(6):434-441.
11. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004;93:679-684.
12. Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004;94:358-360.
13. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-1295.
14. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
15. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
16. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-251.
17. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
18. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.
19. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
20. Motovska Z, Widimsky P, Petr R, et al. on behalf of the PRAGUE-8 Study Investigators. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". J Cardiovasc Pharmacol. 2009 Feb 25. [Epub ahead of print].
21. Motovska Z, Widimsky P, Petr R, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. Int J Cardiol. 2009 Feb 14. [Epub ahead of print].
22. Davì G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96(1):69-75.
23. Soffer D, Moussa I, Harjai K, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv. 2003;59:21-25.
24. Montalescot G, Sideris G, Meuleman C, et al; for the ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938.
25. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27(20):2420-2425.
26. Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol. 2007;50:1541-1547.
27. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112(19):2946-2950.
28. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312-2317.
29. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35:1096-1104.
30. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. Cardiovasc Drug Rev. 2007;25(4):357-374.
31. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:e9-e16.
32. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
33. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo anti-platelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007;5:1545-1551.
34. Muller I, Besta F, Schulz C, Massberg S, Schomig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787.
35. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47(1):27-33.
36. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
37. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
38. Motovska Z, Kala P. Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries. Clin Ther. 2008;30P2:2191-2202.
39. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2007;357:2001-2015.
40. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723-731.
41. US National Institutes of Health. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS). April 20, 2009. Accessed on May 6, 2009. Available from: http://clinicaltrials.gov/ct2/show/ NCT00699998.
42. Wenaweser P, Rey C, Eberli F, et al. Stent thrombosis following bare-metal stent implantation success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005;26(12):1180-1187.
43. Cook S, Windecker S. Early stent thrombosis: Past, present, and future. Circulation. 2009;119:657-659.
44. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
45. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a sub-analysis of a randomised trial. Lancet. 2008;371(9621):1353-1363.
46. Wiviott SD, Braunwald E, Angiolillo DJ, et al; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-1636.
47. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765-775.
48. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
49. Angiolillo DJ, Showmaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS) study. Circulation. 2007;115(6):708-716.
50. Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol. 2007;50:1541-1547.
51. Erlinge D, Varenhorst C, Braun OÖ, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52:1968-1977.
52. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in TRITON-TIMI 38. Circulation. 2008;118:1626-1636.
53. Motovska Z, Widimsky P, Kvasnicka J, et al; on behalf of the PRAGUE-8 study investigators. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism - a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrin. 2009. March 16; doi:10.1097/ MBC.0b013e328325455b.
54. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
55. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
56. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436.
57. Eli Lilly and Company. European Commission approves EFIENT (prasugrel) for patients with acute coronary syndrome undergoing PCI [press release]. February 23, 2009. Accessed on May 6, 2009. Available from: http://newsroom. lilly.com/releasedetail.cfm?ReleaseID=366955.
58. Eli Lilly and Company. Prasugrel receives unanimous approval recommendation from FDA Advisory Committee. February 3, 3009. Accessed on May 6, 2009. Available from: http://www.drugs.com/nda/effient-090204.html.